Guardant Health, Inc. (NASDAQ:GH) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, GH to report 3Q20 loss of $ 0.38 per share.
For the full year, analysts anticipate top line of $ 279.15 million, while looking forward to loss of $ 1.6 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 275.00 million ~ $ 285.00 million
Click Here For More Historical Outlooks Of Guardant Health, Inc.
Previous Quarter Performance
Guardant Health, Inc. announced loss for the second quarter of $ 0.57 per share, from the revenue of $ 66.33 million. The quarterly revenues grew 22.88 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.38 per share from $ 59.17 million in revenue. The bottom line results missed street analysts by $ 0.19 or 50 percent, at the same time, top line results outshined analysts by $ 7.16 million or 12.10 percent.
Stock Performance
Shares of Guardant Health, Inc. traded up $ 5.71 or 5.30 percent on Wednesday, reaching $ 113.40 with volume of 751.80 thousand shares. Guardant Health, Inc. has traded high as $ 115.81 and has cracked $ 109.20 on the downward trend
The closing price of $ 113.40, representing a 92.65 % increase from the 52 week low of $ 55.90 and a 7.01 % decrease over the 52 week high of $ 115.81.
The company has a market capital of $ 11.30 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Recent Analyst recommendations
- On 9th September 2020, initiated by Morgan Stanley at Overweight rating, with $ 110.00 target price.
Conference Call
Guardant Health, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website guardanthealth.com
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors.
